Optic neuritis

Seminars in Neurology

Volumn 27, Issue 3, 2007, Pages 211-220

  Atkins, Edward J ^a   Biousse, Valérie ^b,c   Newman, Nancy J ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY EYE CENTER   (United States)

Author keywords

Multiple sclerosis clinically isolated syndrome; Optic neuritis; Optic neuritis treatment trial

Indexed keywords

IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; STEROID;

DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; INSOMNIA; MOOD CHANGE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STEROID THERAPY; VISUAL ACUITY; VISUAL IMPAIRMENT; WEIGHT GAIN;

HUMANS; OPTIC NEURITIS; VISUAL ACUITY;

EID: 34347354301     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979683     Document Type: Review

References (72)

1. Purvin VA. Optic neuropathies for the neurologist. Semin Neurol 2000;20:97-110
2. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005;4:111-121
3. Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288
4. Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part II: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005;4:341-348
5. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005;139:1101-1108
6. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol 1991;109:1668-1672
7. Ebers GC. Optic neuritis and multiple sclerosis. Arch Neurol 1985;42:702-704
8. Kurtzke JF. Optic neuritis or multiple sclerosis. Arch Neurol 1985;42:704-710
9. Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987;50:758-765
10. Miller DH, Ormerod IEC, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 1988;51:1569-1571
11. Rizzo JF, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988;38:185-190
12. Söderström M, Jin YP, Hillert J, Link H. Optic neuritis, prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998;50:708-714
13. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999;246:770-775
14. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164
15. Tintoré M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005;57:210-215
16. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-588
17. Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997;115:1545-1552
18. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol 2004;137:77-83
19. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997;49:1404-1413
20. Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol 2004;61:1538-1541
21. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 2003;121:944-949
22. Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004;61:1386-1389
23. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993;329:1764-1769
24. Beck RW, Arrington J, Murtagh FR, et al. Brain magnetic resonance imaging in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol 1993;50:841-846
25. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a treatment initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
26. CHAMPS Study Group. Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001;132:463-471
27. Beck RW, Chandler DL, Cole SR, et al. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002;51:481-490
28. CHAMPIONS Study Group. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-684
29. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study (ETOMS). Lancet 2001;357: 1576-1582
30. Kappos L, Polman C, Freedman M, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249
31. Brusaferri F, Candelise F. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435-442
32. Kaufman DI, Trobe JD, Eggenberger ER, et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 2000;54: 2039-2044
33. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52:1479-1484
34. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993;116: 135-146
35. Sandberg-Wollheim M, Bynke H, Cronqvist S, et al. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990;27:386-393
36. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997;41:392-398
37. Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 2005;252:396-402
38. Jin YP, de Pedro-Cuesta J, Huang YH, Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003;9:135-141
39. Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004; 61:217-221
40. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different diagnostic MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21:702-706
41. Korteweg T, Tintoré M, Uitdehaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006;5:221-227
42. Barkhof F, Filippi M, Miller DH, et al. Isolated demyelinating syndromes: comparison of different magnetic resonance imaging criteria to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069
43. McDonald WI, Compston A, Edam G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
44. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846
45. Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003;53:673-676
46. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146
47. Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry 2003;74:1577-1580
48. Frederiksen JL. Can CSF predict the course of optic neuritis? Mult Scler 1998;4:132-135
49. Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996;46:368-372
50. Cole SR, Beck RW, Moke PS, et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998;51:885-887
51. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006;66: 576-578
52. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-1520
53. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281
54. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9:565-572
55. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005;64:804-810
56. Revesz T. Axonal lesions in MS: an old story revisited. Brain 2000;123:203-204
57. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70
58. Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68: 157-161
59. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62:1371-1376
60. Frohman EM, Racke M, van Den Noort S. To treat or not to treat? The therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol 2000;57:930-932
61. Balcer LJ. Clinical practice: optic neuritis. N Engl J Med 2006;354:1273-1280
62. Montalban X. The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol 2004;251(suppl 4):IV30-IV34
63. van Engelen BG, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992;32:834-835
64. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990;27:12-17
65. Rodriguez M, Miller DJ. Immune promotion of central nervous system remyelination. Prog Brain Res 1994;103:343-355
66. van Engelen BG, Miller DJ, Pavelko KD, et al. Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus-induced demyelination and in MS. J Neurol Neurosurg Psychiatry 1994;57(suppl 1):65-68
67. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996;46:538-545
68. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56: 1514-1522
69. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003;18:174-180
70. Brady KM, Brar AS, Lee AG, et al. Optic neuritis in children: clinical features and visual outcome. J AAPOS 1999;3:98-103
71. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000;37:254-259
72. Lucchinetti CF, Kiers L, O'Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997;49:1413-1418